vs
美国银行（BAC）与礼来（LLY）财务数据对比。点击上方公司名可切换其他公司
美国银行的季度营收约是礼来的1.6倍（$31.2B vs $19.3B），礼来净利率更高（34.4% vs 24.1%，领先10.3%），过去两年礼来的营收复合增速更高（48.3% vs 11.3%）
美国银行是美国知名跨国投资银行及金融服务控股集团，总部位于北卡罗来纳州夏洛特的美国银行企业中心，在曼哈顿设有投行业务及辅助办公总部，1998年由国民银行与原美国银行合并组建，为全球客户提供多元化综合金融服务。
礼来（Eli Lilly and Company）是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业，1876年由美国内战时期联邦军退伍药剂师伊莱·礼来创立，目前在18个国家设有办事处，产品销往全球约125个国家，是全球知名的制药厂商。
BAC vs LLY — 直观对比
营收规模更大
BAC
是对方的1.6倍
$19.3B
净利率更高
LLY
高出10.3%
24.1%
两年增速更快
LLY
近两年复合增速
11.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $31.2B | $19.3B |
| 净利润 | $7.5B | $6.6B |
| 毛利率 | — | 82.5% |
| 营业利润率 | 39.9% | 42.8% |
| 净利率 | 24.1% | 34.4% |
| 营收同比 | — | 42.6% |
| 净利润同比 | — | 50.5% |
| 每股收益（稀释后） | $0.96 | $7.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BACLLY
| Q4 25 | $31.2B | $19.3B | ||
| Q3 25 | $28.1B | $17.6B | ||
| Q2 25 | $26.5B | $15.6B | ||
| Q1 25 | $27.4B | $12.7B | ||
| Q4 24 | — | $13.5B | ||
| Q3 24 | $25.3B | $11.4B | ||
| Q2 24 | $25.4B | $11.3B | ||
| Q1 24 | $25.8B | $8.8B |
净利润BACLLY
| Q4 25 | $7.5B | $6.6B | ||
| Q3 25 | $8.5B | $5.6B | ||
| Q2 25 | $7.1B | $5.7B | ||
| Q1 25 | $7.4B | $2.8B | ||
| Q4 24 | — | $4.4B | ||
| Q3 24 | $6.9B | $970.3M | ||
| Q2 24 | $6.9B | $3.0B | ||
| Q1 24 | $6.7B | $2.2B |
毛利率BACLLY
| Q4 25 | — | 82.5% | ||
| Q3 25 | — | 82.9% | ||
| Q2 25 | — | 84.3% | ||
| Q1 25 | — | 82.5% | ||
| Q4 24 | — | 82.2% | ||
| Q3 24 | — | 81.0% | ||
| Q2 24 | — | 80.8% | ||
| Q1 24 | — | 80.9% |
营业利润率BACLLY
| Q4 25 | 39.9% | 42.8% | ||
| Q3 25 | 33.7% | 41.1% | ||
| Q2 25 | 29.1% | 43.6% | ||
| Q1 25 | 29.7% | 27.2% | ||
| Q4 24 | — | 37.2% | ||
| Q3 24 | 28.9% | 13.9% | ||
| Q2 24 | 29.8% | 31.1% | ||
| Q1 24 | 28.1% | 28.9% |
净利率BACLLY
| Q4 25 | 24.1% | 34.4% | ||
| Q3 25 | 30.2% | 31.7% | ||
| Q2 25 | 26.9% | 36.4% | ||
| Q1 25 | 27.0% | 21.7% | ||
| Q4 24 | — | 32.6% | ||
| Q3 24 | 27.2% | 8.5% | ||
| Q2 24 | 27.2% | 26.3% | ||
| Q1 24 | 25.9% | 25.6% |
每股收益（稀释后）BACLLY
| Q4 25 | $0.96 | $7.39 | ||
| Q3 25 | $1.06 | $6.21 | ||
| Q2 25 | $0.89 | $6.29 | ||
| Q1 25 | $0.90 | $3.06 | ||
| Q4 24 | — | $4.88 | ||
| Q3 24 | $0.81 | $1.07 | ||
| Q2 24 | $0.83 | $3.28 | ||
| Q1 24 | $0.76 | $2.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $7.3B |
| 总债务越低越好 | $317.8B | — |
| 股东权益账面价值 | $303.2B | $26.5B |
| 总资产 | $3411.7B | $112.5B |
| 负债/权益比越低杠杆越低 | 1.05× | — |
8季度趋势，按日历期对齐
现金及短期投资BACLLY
| Q4 25 | — | $7.3B | ||
| Q3 25 | — | $9.9B | ||
| Q2 25 | — | $3.5B | ||
| Q1 25 | — | $3.2B | ||
| Q4 24 | — | $3.4B | ||
| Q3 24 | — | $3.5B | ||
| Q2 24 | — | $3.4B | ||
| Q1 24 | — | $2.6B |
总债务BACLLY
| Q4 25 | $317.8B | — | ||
| Q3 25 | $311.5B | — | ||
| Q2 25 | $313.4B | — | ||
| Q1 25 | $304.1B | — | ||
| Q4 24 | — | $29.5B | ||
| Q3 24 | $296.9B | — | ||
| Q2 24 | $290.5B | — | ||
| Q1 24 | $296.3B | — |
股东权益BACLLY
| Q4 25 | $303.2B | $26.5B | ||
| Q3 25 | $304.2B | $23.8B | ||
| Q2 25 | $299.6B | $18.3B | ||
| Q1 25 | $295.6B | $15.8B | ||
| Q4 24 | — | $14.2B | ||
| Q3 24 | $296.5B | $14.2B | ||
| Q2 24 | $293.9B | $13.6B | ||
| Q1 24 | $293.6B | $12.8B |
总资产BACLLY
| Q4 25 | $3411.7B | $112.5B | ||
| Q3 25 | $3403.7B | $114.9B | ||
| Q2 25 | $3441.1B | $100.9B | ||
| Q1 25 | $3349.4B | $89.4B | ||
| Q4 24 | — | $78.7B | ||
| Q3 24 | $3324.3B | $75.6B | ||
| Q2 24 | $3258.0B | $71.9B | ||
| Q1 24 | $3273.8B | $63.9B |
负债/权益比BACLLY
| Q4 25 | 1.05× | — | ||
| Q3 25 | 1.02× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | — | 2.08× | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.99× | — | ||
| Q1 24 | 1.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.9B | $3.2B |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | -3.05× | 0.49× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BACLLY
| Q4 25 | $-22.9B | $3.2B | ||
| Q3 25 | $46.9B | $8.8B | ||
| Q2 25 | $-9.1B | $3.1B | ||
| Q1 25 | $-2.2B | $1.7B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $3.7B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | $-15.5B | $1.2B |
现金转化率BACLLY
| Q4 25 | -3.05× | 0.49× | ||
| Q3 25 | 5.53× | 1.58× | ||
| Q2 25 | -1.28× | 0.55× | ||
| Q1 25 | -0.30× | 0.60× | ||
| Q4 24 | — | 0.56× | ||
| Q3 24 | — | 3.83× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | -2.33× | 0.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BAC
| Other | $7.0B | 22% |
| Global Wealth And Investment Management Segment | $6.6B | 21% |
| Global Banking Segment | $6.2B | 20% |
| Global Markets Segment | $5.3B | 17% |
| Investment And Brokerage Services Asset Management Fees | $4.2B | 13% |
| Investment Banking Income Underwriting Income | $752.0M | 2% |
| Investment Banking Income Financial Advisory Services | $590.0M | 2% |
| Investment Banking Income Syndication Fees | $324.0M | 1% |
| Corporate Securities Trading Loansand Other | $184.0M | 1% |
| Mortgage Trading Loans Mortgage Backed Securities And Asset Backed Securities | $31.0M | 0% |
| Equity Securities | $12.0M | 0% |
| Accrued Expensesand Other Liabilities | $11.0M | 0% |
LLY
| Other | $5.4B | 28% |
| Zepbound | $4.2B | 22% |
| Mounjaro | $4.1B | 21% |
| Verzenio | $997.1M | 5% |
| Collaborationand Other Revenue | $991.7M | 5% |
| Taltz | $724.3M | 4% |
| Trulicity | $692.8M | 4% |
| Other Cardiometabolic Health | $524.5M | 3% |
| Other Oncology | $514.8M | 3% |
| Jardiance | $465.8M | 2% |
| Neuroscience | $320.2M | 2% |
| Other Immunology | $187.3M | 1% |
| Other Product Total | $77.0M | 0% |
